[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 15, 1984

Pertussis and Pertussis Vaccine: Reanalysis of Benefits, Risks, and Costs

Author Affiliations

From the Division of Immunization, Center for Prevention Services (Dr Hinman); and the Office of the Director (Dr Koplan), Centers for Disease Control, Atlanta.

JAMA. 1984;251(23):3109-3113. doi:10.1001/jama.1984.03340470035022

Using recently published information, we examined the experience of a hypothetical cohort of 1 million children followed up from birth to 6 years of age without and with a pertussis vaccination program. Costs associated with death or lost wages were not estimated. A vaccination program reaching 90% of children would reduce disease incidence and disease-related costs by 90%. Taking into account costs associated with vaccine and vaccine reactions, the costs are reduced 82%. The ratio of overall costs without a program to those with a program is 5.7:1. The benefit-cost ratio is 11.1:1. Because we did not include indirect costs, this is a conservative estimate. Until improved vaccines are available, continued use of our present vaccines, with careful attention to possible contraindications, seems the only prudent course to follow.

(JAMA 1984;251:3109-3113)